Literature DB >> 9350435

Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human erythropoietin.

E Uchida1, K Morimoto, N Kawasaki, Y Izaki, A Abdu Said, T Hayakawa.   

Abstract

Our previous study showed that active oxygen radicals generated from a Fenton system and a xanthine plus xanthine oxidase system caused serious loss of in vivo bioactivity of recombinant human erythropoietin (EPO), a highly glycosylated protein. In the present study, we characterized the oxidative modifications to the protein and carbohydrate moiety of EPO, which lead to a reduction of its bioactivity. In vitro bioactivity was reduced when EPO was treated with oxygen radicals generated from a Fenton system in the presence of 0.016 mM H2O2, and the reduction was directly proportional to the loss of in vivo bioactivity. SDS-PAGE analysis showed that dimer formation and degradation was observed under more severe conditions (Fenton reaction with 0.16 mM H2O2). The tryptophan destruction was detected at 0.016 mM H2O2 and well correlated with the loss of in vitro bioactivity, whereas loss of other amino acids were occurred under more severe conditions. Treatment with the Fenton system did not result in any specific damage on the carbohydrate moiety of EPO, except a reduction of sialic acid content under severe condition. These results suggest that active oxygen radicals mainly react with the protein moiety rather than the carbohydrate moiety of EPO. Destruction of tryptophan residues is the most sensitive marker of oxidative damage to EPO, suggesting the importance of tryptophan in the active EPO structure. Deglycosylation of EPO caused an increased of susceptibility to oxygen radicals compared to intact EPO. The role of oligosaccharides in EPO may be to protect the protein structure from active oxygen radicals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350435     DOI: 10.3109/10715769709065769

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  24 in total

Review 1.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

Review 2.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

3.  Glycosylation of Therapeutic Proteins: A Critical Quality Attribute.

Authors:  Arnaud Delobel
Journal:  Methods Mol Biol       Date:  2021

4.  Effects of UVA irradiation, aryl azides, and reactive oxygen species on the orthogonal inactivation of the human immunodeficiency virus (HIV-1).

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; M Jason de la Cruz; Kunio Nagashima; Robert Blumenthal
Journal:  Virology       Date:  2011-07-02       Impact factor: 3.616

Review 5.  Erythropoietin and diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  World J Diabetes       Date:  2015-10-25

6.  Charting a course for erythropoietin in traumatic brain injury.

Authors:  Kenneth Maiese
Journal:  J Transl Sci       Date:  2016-03-26

Review 7.  Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2016       Impact factor: 1.990

8.  Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase.

Authors:  Ken Aizawa; Ryohei Kawasaki; Yoshihito Tashiro; Michinori Hirata; Koichi Endo; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2016-04-15       Impact factor: 2.490

Review 9.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.